التفاصيل البيبلوغرافية
| العنوان: |
Evolution in the Surgical Management of Gastric Cancer Peritoneal Metastases. |
| المؤلفون: |
Krell, Matthew, Ranjbar, Suedeh, Gitlin, Saige, Alvarez Vega, Diego R., Wilson, Rachel, Thrasher, Kenya, Brown, Zachary J. |
| المصدر: |
Cancers; Jan2025, Vol. 17 Issue 1, p100, 15p |
| مصطلحات موضوعية: |
PREVENTIVE medicine, STOMACH tumors, INTRAPERITONEAL injections, SURGERY, THERMOTHERAPY, AEROSOLS, CYTOREDUCTIVE surgery, METASTASIS, CANCER chemotherapy, ADJUVANT chemotherapy, COMBINED modality therapy, PERITONEUM tumors |
| مستخلص: |
Simple Summary: Gastric cancer (GC) is a deadly disease with a high mortality rate, particularly when it spreads to the peritoneum, a condition known as peritoneal metastasis (PM). Current treatments are not very effective, and patients with GC/PM often have a poor prognosis with survival of only 4 to 10 months. This review explores emerging therapies for peritoneal metastases directly, including heated intraperitoneal chemotherapy (HIPEC) and newer methods like pressurized intraperitoneal aerosolized chemotherapy (PIPAC). The goal is to provide more effective treatment options for patients with GC/PM to improve survival rates and quality of life. The findings could lead to better treatment strategies and offer valuable insights to researchers in the field. Despite therapeutic treatments and the growing utilization of multimodal therapies, gastric cancer (GC) remains a highly aggressive malignancy with high mortality worldwide. Much of the complexity in treating GC is due to the high incidence of peritoneal metastasis (PM), with mean overall survival typically ranging from 4 to 10 months. With current systemic therapy, targeted therapies, and immunotherapies continuing to remain ineffective for GC/PM, there has been a significant growing interest in intraperitoneal (IP) therapies for the treatment of GC/PM. In this review, we summarize the development of PM and evolving treatment strategies for GC/PM. Furthermore, we explore the various advancements and outcomes of IP therapies, including heated intraperitoneal chemotherapy (HIPEC), neoadjuvant HIPEC, and pressurized intraperitoneal aerosolized chemotherapy (PIPAC). [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder